[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.75.58. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

February 2020, Vol 77, No. 2, Pages 149-265

In This Issue of JAMA Neurology

Highlights

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):149. doi:10.1001/jamaneurol.2019.3183
Viewpoint

Insidious Cerebrovascular Disease—The Uncool Iceberg

Abstract Full Text
JAMA Neurol. 2020;77(2):155-156. doi:10.1001/jamaneurol.2019.3933

This Viewpoint describes the clinical and public health implications of emerging information on subclinical cases of cerebrovascular disease.

Microgravity and Cosmic Radiations During Space Exploration as a Window Into Neurodegeneration on Earth

Abstract Full Text
JAMA Neurol. 2020;77(2):157-158. doi:10.1001/jamaneurol.2019.4003

This Viewpoint encourages researchers to take the opportunity to investigate brain adaptation to long-term spaceflight as a model of aging.

On the Brain

Hail Mary

Abstract Full Text
JAMA Neurol. 2020;77(2):159. doi:10.1001/jamaneurol.2019.3950

This essay describes an interaction the author had with a patient’s family members in deciding whether to pursue surgey for the patient.

Editorial

Prevention of Dementia—Thinking Beyond the Age and Amyloid Boxes

Abstract Full Text
JAMA Neurol. 2020;77(2):160-161. doi:10.1001/jamaneurol.2019.3785

Pragmatic Trials and Repurposed Drugs for Alzheimer Disease

Abstract Full Text
JAMA Neurol. 2020;77(2):162-163. doi:10.1001/jamaneurol.2019.3784
Original Investigation

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Neurol. 2020;77(2):164-174. doi:10.1001/jamaneurol.2019.3762

This randomized clinical trial examines whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild Alzheimer disease.

Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort

Abstract Full Text
open access
JAMA Neurol. 2020;77(2):175-183. doi:10.1001/jamaneurol.2019.3774

This longitudinal cohort study assesses the associations between vascular risk in early adulthood, midlife, and late life with late-life brain structure and β-amyloid load and white matter hyperintensity, whole-brain, and hippocampal volumes.

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Abstract Full Text
JAMA Neurol. 2020;77(2):184-191. doi:10.1001/jamaneurol.2019.3365

This registry-based cohort study examines the risk of serious infections associated with disease-modifying treatments for multiple sclerosis in Sweden.

Risk of Developing Parkinson Disease in Bipolar Disorder: A Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Neurol. 2020;77(2):192-198. doi:10.1001/jamaneurol.2019.3446

This systematic review and meta-analysis assesses the association of bipolar disorder with a later diagnosis of idiopathic Parkinson disease.

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Abstract Full Text
open access has active quiz has audio
JAMA Neurol. 2020;77(2):199-209. doi:10.1001/jamaneurol.2019.3988

The AMARANTH and DAYBREAK-ALZ randomized clinical trials assess whether lanabecestat slows the progression of Alzheimer disease compared with placebo in patients with early Alzheimer disease or mild Alzheimer disease dementia.

Association of Seropositivity to Borrelia burgdorferi With the Risk of Neuropsychiatric Disorders and Functional Decline in Older Adults: The Aging Multidisciplinary Investigation Study

Abstract Full Text
JAMA Neurol. 2020;77(2):210-214. doi:10.1001/jamaneurol.2019.3292

This prospective cohort study examines the association between seropositivity to Borrelia burgdorferi and incidental neuropsychiatric disorders and functional decline in rural southwestern France.

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial

Abstract Full Text
JAMA Neurol. 2020;77(2):215-224. doi:10.1001/jamaneurol.2019.3812

This parallel-design, double-blind randomized clinical trial assesses the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 in patients with Alzheimer disease or the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome.

Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease

Abstract Full Text
open access
JAMA Neurol. 2020;77(2):225-233. doi:10.1001/jamaneurol.2019.3606

This cross-sectional study using tissue from the Florida Autopsied Multi-Ethnic cohort assesses whether an association exists between neuropathologic subtypes of Alzheimer disease and neurofibrillary tangle accumulation or neuron loss in the nucleus basalis of Meynert, a major source of brain cholinergic innervation.

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis

Abstract Full Text
JAMA Neurol. 2020;77(2):234-244. doi:10.1001/jamaneurol.2019.3283

This cohort study comprehensively assesses key biological and methodologic aspects of trials of acute optic neuritis for testing neuroprotection and remyelination in multiple sclerosis.

Review

Association Between Cigarette Smoking and Multiple Sclerosis: A Review

Abstract Full Text
JAMA Neurol. 2020;77(2):245-253. doi:10.1001/jamaneurol.2019.4271

This narrative review discusses the risk for and progression of multiple sclerosis in association with cigarette smoking.

Images in Neurology

Dopamine-Mediated Yawning-Fatigue Syndrome With Specific Recurrent Initiation and Responsiveness to Opioids

Abstract Full Text
has multimedia
JAMA Neurol. 2020;77(2):254. doi:10.1001/jamaneurol.2019.3937

This case report describes a man with recurrent attacks of yawning and fatigue that were mediated by dopamine and responsive to opioid treatment.

CRMP5-IgG–Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy

Abstract Full Text
JAMA Neurol. 2020;77(2):255-256. doi:10.1001/jamaneurol.2019.4379

This case report describes CRMP5-IgG–associated paraneoplastic myelopathy with PD-L1 inhibitor therapy in a woman in her 60s.

Research Letter

Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients

Abstract Full Text
JAMA Neurol. 2020;77(2):257-259. doi:10.1001/jamaneurol.2019.3656

This study characterizes the frequency and sex ratio of positive test results for myelin oligodendrocyte glycoprotein–IgG and aquaporin-4–IgG in adult and pediatric patient populations in a single center.

Perception of Dementia Risk and Preventive Actions Among US Adults Aged 50 to 64 Years

Abstract Full Text
JAMA Neurol. 2020;77(2):259-262. doi:10.1001/jamaneurol.2019.3946

This study examines the perception of US individuals about their likelihood of developing dementia and their strategies to improve or maintain memory.

Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome

Abstract Full Text
JAMA Neurol. 2020;77(2):262-264. doi:10.1001/jamaneurol.2019.3666

This cohort study uses Medicare data to examine the incidence and prevalence of Alzheimer disease and all forms of dementia in individuals with Down syndrome.

Comment & Response

The Term Traumatic in Mild Traumatic Brain Injury and the Misrepresentation of Outcomes

Abstract Full Text
JAMA Neurol. 2020;77(2):264. doi:10.1001/jamaneurol.2019.4454

The Term Traumatic in Mild Traumatic Brain Injury and the Misrepresentation of Outcomes—Reply

Abstract Full Text
JAMA Neurol. 2020;77(2):264-265. doi:10.1001/jamaneurol.2019.4457
Correction

Error in Text

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):265. doi:10.1001/jamaneurol.2019.4034

Error in Results

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):265. doi:10.1001/jamaneurol.2019.4597

Missing Funding Information in Funding/Support

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):265. doi:10.1001/jamaneurol.2019.4769

Errors in Titles

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):265. doi:10.1001/jamaneurol.2020.0045
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2020;77(2):150. doi:10.1001/jamaneurol.2019.3184
×